Myriad Genetics, Inc. (MYGN)

Market Cap	1.90B
Revenue (ttm)	678.40M
Net Income (ttm)	-112.00M
Shares Out	81.22M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	40.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	388,838
Open	23.80
Previous Close	23.75
Day's Range	23.17 - 23.96
52-Week Range	13.92 - 28.18
Beta	1.83
Analysts	Sell
Price Target	20.97 (-10.35%)
Earnings Date	May 4, 2023

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancrea...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 5, 1995
• Employees: 2,400
• Stock Exchange: NASDAQ
• Ticker Symbol: MYGN

Financial Performance

In 2022, MYGN's revenue was $678.40 million, a decrease of -1.77% compared to the previous year's $690.60 million. Losses were -$112.00 million, 311.8% more than in 2021.

Analyst Forecast

According to 14 analysts, the average rating for MYGN stock is "Sell." The 12-month stock price forecast is $20.97, which is a decrease of -10.35% from the latest price.

Price Target

$20.97

(-10.35% downside)

Analyst Consensus: Sell